PharmSource - Cell Therapy Market Opportunity for CMOs - 2018 Edition

PharmSource - Cell Therapy Market Opportunity for CMOs - 2018 Edition

  • Products Id :- GDPS0021MAR
  • |
  • Pages: 70
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

PharmSource-Cell Therapy Market Opportunity for CMOs-2018 Edition


This PharmSource Trend Report will explore whether the bio/pharma industry is adequately prepared for future cell therapy developments and whether pharma companies and contract manufacturing organizations (CDMOs) are making appropriate investments in the capacity and technology to support the coming opportunity.

This 35-page report gives important, expert insight you won't find in any other source. 16 tables and figures throughout the report illustrate major points and trends.


This report seeks to achieve the following objectives-

- To describe and evaluate the cell therapy market opportunity;

- To describe and address the adequacy of the network of CDMOs that manufacture for the cell therapy market, both clinical and commercial;

- To assess the outlook for buyers and sellers of contract manufacturing services for cell therapies, including the supply/demand balance.

Reasons to buy

This report is required reading for-

- CMO executives who must have deep understanding of the Cell Therapy marketplace to make strategic planning and investment decisions.

- Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.

- Pharmaceutical and Biotech companies involved in the development of Cell Therapies or Cell Therapy technologies.

- Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

1. Executive Summary 4

2. Introduction 5

3. Commercial Cell Therapy Experience 7

4. Cell Therapy Pipeline 10

5. Next-Generation Technologies 13

6. Approvals Outlook 15

7. Cell Therapy Supply Chain 16

8. Demand Models 23

9. What It Means 25

10. Notes on Methodology 28

11. Appendix 32

List of Figures

Figure 1: Kymriah Global Sales Forecast 2018-2024 (USDB) 8

Figure 2: Yescarta Global Sales Forecast 2018-2024 (USDB) 9

Figure 3: Pipeline Cell Therapy Candidates 10

Figure 4: Phase I Trial Starts by Sponsor Type 11

Figure 5: Phase II Planned Trial Starts by Sponsor Type 12

Figure 6: Phase III Planned Trial Starts by Sponsor Type 12

List of Tables

Table 1 : FDA-Approved, Marketed Cell Therapies 7

Table 2: Cell Therapy Approvals 15

Table 3: Cell Therapy CDMOs' Biological Services 17

Table 5: Cell Therapy CDMOs' Packaging Capabilities 19

Table 6: Cell Therapy CDMO Sites and Associated Cell Source and Types 21

Table 7: Method of Transfection Used at Cell Therapy CDMO Sites 23

Table 8: Model for Cell Therapy Clinical Requirements 24

Table 9: Model for Cell Therapy Commercial Requirements 25

Table 10: Model for Yearly Cell Therapy Commercial Requirements 31

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]


China PLA General Hospital


3P Biopharmaceuticals


Anemocyte SRL

apceth Biopharma GmbH

Areta International

Army Military Medical University (formerly Third Military Medical University)


Atvio Biotech Ltd

Austrianova Singapore Pte. Ltd.


Bio Elpida

Bioinova sro

Brammer Bio



Cell and Gene Therapy Catapult


Cellin Technologies LLC

Cellular Therapeutics Ltd.


City of Hope

Cognate Bioservices

Cook General BioTechnology, LLC

Dendreon Pharmaceuticals LLC


Fraunhofer Group

GE Healthcare


Gilead Sciences Inc.

Histocell SL

Hitachi Chemical Co Ltd

Hitachi Chemical Co., Ltd.

Holostem Terapie Avanzate

Incell Corporation LLC

International Stem Cell Corporation

Japan Tissue Engineering

Johnson & Johnson

KBI Biopharma


Kite Pharma Inc.

Lonza Group

Lonza Netherlands



MolMed SpA

New York Blood Center, Inc

Newcastle University

NHS Blood and Transplant

Nikon Corporation

Novartis International AG

Novartis Pharmaceuticals Corp.

Organogenesis Inc.

Oxford Biomedica


Provia Laboratories LLC

Roslin Cell Therapies

Sanpower Group Co Ltd

Sanquin Blood Supply Foundation

Shenzhen Geno-Immune Medical Institute

Stem Cell and Cancer Institute (SCI)

Takara Bio

University College London

University of Edinburgh

University of Miami Health System

University of Minnesota

University of Pittsburgh

University of Utah Health

Vericel Corp.

WuXi AppTec


AAV, Electroporation, Lentivector, Retrovirus, Cryovials, Prefilled syringe, Vials, Closed-system bag Filling, Cryobags, Analytical methods development, Biosafety testing, Cell banking, Cell line development, Fill and finish, Formulation development, Microbiology, Process development, Stability testing, Allogeneic Cell Source, Autologous Cell Source, Dendritic cells, Embryonic stem cells, Mesenchymal Stromal cells, NK cells, T cells, Provenge, Yescarta, Kymriah, Maci, Gintuit, Carticel, chimeric antigen receptors T cell (CAR-T)

select a license
Single User License
USD 4995 INR 345704
Site License
USD 9990 INR 691408
Corporate User License
USD 14985 INR 1037112



The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]